Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?

Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?

<h4>Objective</h4>Patients living with rheumatologic diseases on disease-modifying antirheumatic drugs (DMARD) are at an increased risk of developing tuberculosis (TB). Current guidelines recommend screening for latent tuberculosis infection (LTBI) before initiating DMARD. However, data...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlo Foppiano Palacios, Vaidehi Chowdhary, Ritche Hao, Abhijeet Danve, Maricar Malinis
Formato: Artículo
Lenguaje:English
Publicado: Public Library of Science (PLoS) 2024-01-01
Colección:PLoS ONE
Acceso en línea:https://doi.org/10.1371/journal.pone.0306337

Ejemplares similares

Ejemplares similares